[HTML][HTML] Tumor microenvironment: barrier or opportunity towards effective cancer therapy
Tumor microenvironment (TME) is a specialized ecosystem of host components, designed
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …
by tumor cells for successful development and metastasis of tumor. With the advent of 3D …
A review of cancer immunotherapy: from the past, to the present, to the future
K Esfahani, L Roudaia, N Buhlaiga, SV Del Rincon… - Current …, 2020 - mdpi.com
A review of cancer immunotherapy: from the past, to the present, to the future Page 1 S87
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …
[HTML][HTML] Multi-omic machine learning predictor of breast cancer therapy response
Breast cancers are complex ecosystems of malignant cells and the tumour
microenvironment. The composition of these tumour ecosystems and interactions within …
microenvironment. The composition of these tumour ecosystems and interactions within …
[HTML][HTML] Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Abstract Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features …
NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand …
Major histocompatibility complex (MHC) molecules are expressed on the cell surface, where
they present peptides to T cells, which gives them a key role in the development of T-cell …
they present peptides to T cells, which gives them a key role in the development of T-cell …
[PDF][PDF] A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer
PA Ott, S Hu-Lieskovan, B Chmielowski, R Govindan… - Cell, 2020 - cell.com
Neoantigens arise from mutations in cancer cells and are important targets of T cell-
mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a …
mediated anti-tumor immunity. Here, we report the first open-label, phase Ib clinical trial of a …
[HTML][HTML] SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
T cell immunity is central for the control of viral infections. To characterize T cell immunity,
but also for the development of vaccines, identification of exact viral T cell epitopes is …
but also for the development of vaccines, identification of exact viral T cell epitopes is …
[HTML][HTML] Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer
S Li, W Yu, F Xie, H Luo, Z Liu, W Lv, D Shi… - Nature …, 2023 - nature.com
Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …
Y chromosome loss in cancer drives growth by evasion of adaptive immunity
Loss of the Y chromosome (LOY) is observed in multiple cancer types, including 10–40% of
bladder cancers,,,,–, but its clinical and biological significance is unknown. Here, using …
bladder cancers,,,,–, but its clinical and biological significance is unknown. Here, using …
Therapeutics data commons: Machine learning datasets and tasks for drug discovery and development
Therapeutics machine learning is an emerging field with incredible opportunities for
innovatiaon and impact. However, advancement in this field requires formulation of …
innovatiaon and impact. However, advancement in this field requires formulation of …